Fairbrother, US
Jeffrey L. Fairbrother, Raleigh, NC US
Patent application number | Description | Published |
---|---|---|
20080201450 | OWNER CONTROLLED ACCESS TO SHARED DATA RESOURCE - A method, system and computer program product for controlling an access to a data resource are disclosed. According to an embodiment, a method for controlling an access to a data resource comprises: communicating a request for the access to the data resource from a requester to an owner of the data resource for validation, the communicating being implemented by a network server; and generating information required by an access implementation server to implement a validated access and updating a data storage device with the generated information. | 08-21-2008 |
Richard G. Fairbrother, Vestal, NY US
Patent application number | Description | Published |
---|---|---|
20090204463 | METHOD, TOOL, AND SYSTEM FOR ANALYZING A PROJECT - A tool for performing project management analysis on a project. Also disclosed are a system and a method of analyzing the project. The tool includes a project manager implemented to receive project data relating to a schedule, a discrete event simulator to create a model of the project using the project data and to perform a simulation with the model, a database, and an interface to promote interaction between the project manager, the discrete event simulator, and the database. | 08-13-2009 |
20140278290 | SYSTEM AND METHOD FOR INTEGRATED MODELING AND ANALYSIS - An integrated modeling and analysis system (IMAS) receives documents containing information relating to an overall operations system from a number of integrated product teams (IPTs). The IMAS creates a model architecture of the overall system the information received from the participating IPTs. The IMAS automatically imports the information without any interaction from support personnel. A discrete event modeling (DES) application in communication with the IMAS creates a DES model based on the model architecture in the IMAS. The DES application runs a simulation on the model generating statistical data relating to the overall system for analysis. The statistical data generates output reports in a format compatible with the analysis tools of the user. The IMAS includes a customizable user interface which allows a stakeholder to link and control the modeling information received from all other participating IPTs. Prior simulations and results can be archived for later reference. | 09-18-2014 |
Wayne Fairbrother, Burlingame, CA US
Patent application number | Description | Published |
---|---|---|
20090148921 | Compositions and methods for enhancing apoptosis - The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same. | 06-11-2009 |
20110039324 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS - The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same. | 02-17-2011 |
20110098305 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member. | 04-28-2011 |
20120058953 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS - The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same. | 03-08-2012 |
Wayne J. Fairbrother, Burlingame, CA US
Patent application number | Description | Published |
---|---|---|
20080280856 | Fibroblast Activation Protein Inhibitor Compounds and Methods - Amino terminus-blocked peptide boronate compounds of Formulas I and II are useful for inhibiting Fibroblast Activation Protein (FAP) and other proteases, and for treating disorders mediated by FAP. Methods of using the amino terminus blocked peptide boronate compounds, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 11-13-2008 |
20100056517 | ARYLSULFONAMIDE COMPOUNDS - The invention relates generally to small molecules that mimic the biological activity of certain peptides and proteins, to compositions containing them and to their use. In particular, the invention relates to compounds of the general formula (I) that mimic the biological activity of BH3-only proteins and are capable of binding to and neutralizing pro-survival Bcl-2 proteins: | 03-04-2010 |
20100190782 | COMPOUNDS AND METHODS OF USE - In one aspect, the present invention provides for a compound of Formula I | 07-29-2010 |
20100210622 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE - In one aspect, the present invention provides for a compound of Formula I | 08-19-2010 |
20120184541 | COMPOUNDS AND METHODS OF USE - In one aspect, the present invention provides for a compound of Formula I | 07-19-2012 |
20120202750 | INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: | 08-09-2012 |
20130143824 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS - The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same. | 06-06-2013 |
20140005190 | COMPOUNDS AND METHODS OF USE | 01-02-2014 |
Wayne John Fairbrother, South San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20140248262 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer. | 09-04-2014 |
William Fairbrother, Barrington, RI US
Patent application number | Description | Published |
---|---|---|
20130096838 | Gene Splicing Defects - Predicting the effect of a mutation in a nucleic acid sequence on splicing is accomplished by determining the distance between at least two nucleic acid sequence positional distributions and providing a prediction of impact on splicing function based on at least the distance. A low distance indicates there is little or no difference in splicing function compared to a normal control. A high distance indicates a difference in splicing function. Related apparatus, systems, techniques and articles are also described. | 04-18-2013 |